Skip to content
CompoundSci
All peptides
Research vial labelled Sermorelin, a Growth hormone secretagogue peptide studied in preclinical and clinical literature

Sermorelin

GRF 1-29

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

The oldest GHRH analog in clinical use, which is why the paediatric safety record is the deepest of this class.

General profile

Class
Growth hormone secretagogue
Evidence
Mixed or moderate evidence
Studied dose range
0.1–0.3 mg
Frequency in protocols
Nightly, fasted
Route
Subcutaneous
Half life
~12 minutes
Reconstitution
2 mL bacteriostatic water per 5 mg vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the bedtime window, fasted

Nightly, fasted

A twelve minute half-life only makes sense if it lands on the natural nocturnal growth-hormone pulse. Carbohydrate within two hours blunts that pulse.

Reported cycle: 12 weeks on, 4 weeks off

GHRH analog protocols are measured in months because IGF-1 responses are slow to appear and slow to fade.

Watch for: Morning puffiness, tingling in the hands, and fasting glucose drifting upward.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopTiming

    Sermorelin + Tesamorelin

    Two GHRH analogs on the same axis

    Both are growth-hormone releasing hormone analogs hitting the same receptor. Running them together raises total exposure without raising the pulse, and desensitisation plus water retention follow.

  • Pick oneRedundant, pick one

    Sermorelin + Tesamorelin

    Same target hit twice

    Same GHRH lane, different half-lives. Running both does not compound the pulse.

  • Pick oneRedundant, pick one

    Sermorelin + CJC-1295 with DAC

    Same target hit twice

    Same GHRH lane.

  • Pick oneRedundant, pick one

    Sermorelin + CJC-1295 without DAC

    Same target hit twice

    Same GHRH lane.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how Sermorelin fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature